Noramco and SPI Pharma have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceutical manufacturers…
Noramco adds 23 compounds to analytical reference standards catalogue
Noramco announced the addition of 23 new compounds to its analytical reference standards catalog – compounds pharmaceutical product developers require to validate product quality and to verify the integrity of production systems…
Noramco introduces controlled substance development solutions at CPhI Worldwide
Noramco is integrating its API development offering to include all of the technologies and services that generic and branded pharmaceutical producers require to advance solutions to market. The specialty API producer today introduced a comprehensive…
Noramco and SPI Pharma sign letter of intent to develop formulation solution packages
Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services…
Noramco introduces a turnkey approach to cannabinoid APIs at CPhI Worldwide
Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.
- 1
- 2